Edesa Biotech, Inc.
(NASDAQ : EDSA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.47%38.450.9%$1234.07m
JNJJohnson & Johnson 0.73%148.630.7%$874.96m
MRKMerck & Co., Inc. -0.05%81.010.7%$634.52m
ABBVAbbVie, Inc. 0.40%92.941.9%$597.83m
BMYBristol-Myers Squibb Co. -0.52%61.011.0%$597.21m
AZNAstraZeneca Plc -1.44%55.401.2%$564.41m
LLYEli Lilly & Co. 0.06%152.971.1%$430.35m
NVSNovartis AG -0.56%82.940.2%$140.44m
GSKGlaxoSmithKline Plc -0.43%40.800.2%$136.90m
MISTMilestone Pharmaceuticals, Inc. 11.36%9.800.0%$133.95m
OPKOPKO Health, Inc. -0.44%5.6311.2%$132.17m
NVONovo Nordisk A/S 1.49%64.640.1%$68.87m
RGENRepligen Corp. -1.23%152.777.2%$68.82m
PRNBPrincipia Biopharma, Inc. 5.33%91.890.0%$63.33m
SNYSanofi 0.02%51.510.2%$55.59m

Company Profile

Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.